Pharmaceutical composition for preventing or treating triple negative breast cancer
Fexuprazan, combined with chemotherapeutic agents, addresses drug resistance in triple-negative breast cancer by enhancing treatment efficacy through synergistic antitumor effects.
Patent Information
- Application Number
- JP2024535743
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-30
- Filing Date
- 2022-12-30
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2042-12-30
AI Technical Summary
Triple-negative breast cancer patients face limited therapeutic options due to drug resistance and high recurrence rates, necessitating new treatment methods, particularly as existing chemotherapies like anthracyclines and taxanes face efficacy decline.
A pharmaceutical composition combining a 4-methoxypyrrole derivative, Fexuprazan, with chemotherapeutic agents such as doxorubicin or docetaxel, leveraging its proton pump inhibitory activity and GPCR inhibition to enhance antitumor effects.
The combination demonstrates synergistic antitumor effects, improving treatment outcomes for triple-negative breast cancer by inhibiting drug resistance and enhancing therapeutic efficacy.
Smart Images

Figure 2024544082000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition that can be usefully used for the prevention or treatment of triple-negative breast cancer. [Background technology]
[0002] Cancer is a disease whose incidence increases every year due to lifestyle and environmental changes, aging, etc., and is the number one cause of death in Korea. In order to conquer cancer, the range of therapeutic options has expanded with the evolution from first-generation chemical anticancer drugs, second-generation targeted anticancer drugs, and third-generation immune anticancer drugs, but the problem of inhibition of therapeutic efficacy due to anticancer drug resistance has been raised. In particular, treatment using chemical anticancer drugs such as doxorubicin is still known as the preferred approach in clinical cancer treatment (breast, bladder, ovarian, lung, stomach cancer, etc.), but the efficacy of anticancer drugs decreases due to the occurrence of intrinsic or acquired multidrug resistance in cancer cells.
[0003] Triple-negative breast cancer is a type of breast cancer that is negative for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), and there are limited therapeutic options available other than existing anti-cancer chemotherapy. Triple-negative breast cancer patients have a high recurrence rate, and new treatments are needed. In addition, the issue of inhibition of therapeutic efficacy due to resistance to anti-cancer drugs is constantly being raised. For triple-negative breast cancer patients who cannot be treated with hormonal therapy for breast cancer treatment, cytotoxic anti-cancer drug monotherapy is applied, or combination therapy with other cytotoxic anti-cancer drugs or combination therapy with targeted drugs is applied, taking into account the clinical condition and biological characteristics. Anthracyclines, including doxorubicin, and taxanes, including docetaxel and paclitaxel, are representative drugs that have been widely used as the most effective cytotoxic anticancer drugs to date, either alone or in combination with other drugs, and are currently the initial treatment drugs for triple-negative breast cancer.
[0004] A variety of combination therapies have been proposed to overcome resistance to anticancer drugs and effectively treat tumors with high genetic heterogeneity. Using such approaches, it is possible to envision treatments for cancers with high mortality rates, such as acute lymphoblastic leukemia and Hodgkin's lymphoma. Recently, it has been reported that among the chemotherapy treatments for triple-negative breast cancer patients, the proton pump inhibitor (PPI) drugs omeprazole and esomeprazole have a clear improvement effect on pathologic complete response (pCR) when administered before AC-T (adriamycin, cyclophosphamide, taxane) treatment. Thus, combination therapies using existing drugs with guaranteed stability are being continuously researched.
[0005] Meanwhile, fexprazan is disclosed in Korean Patent Registration No. 10-1613245 as a 4-methoxypyrrole derivative having proton pump inhibitory activity, and is known to have effects such as gastric damage inhibitory activity, defense factor enhancing effect, and excellent Helicobacter pylori (H. pylori) eradication activity based on the proton pump inhibitory activity.
[0006] Therefore, as a result of intensive research, the present inventors have confirmed that fexprazan shows excellent effects in preventing or treating triple-negative breast cancer when used in combination with a specific chemotherapeutic agent, and have completed the present invention. Summary of the Invention [Problem to be solved by the invention]
[0007] The present invention provides a pharmaceutical composition that can be usefully used for the prevention or treatment of triple-negative breast cancer. [Means for solving the problem]
[0008] In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising i) a compound represented by the following chemical formula 1, or a pharma- ceutical acceptable salt thereof, and ii) a chemotherapeutic agent. [Chemical formula 1] The compound represented by Chemical Formula 1 is named 'Fexuprazan', and its IUPAC name is 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine, which is a substance described in Korean Patent Registration No. 10-1613245.
[0009] The compound is an active ingredient that exhibits the pharmacological effects of the pharmaceutical composition according to the present invention, and has excellent anti-ulcer activity (i.e., proton pump inhibitory activity, etc.), Helicobacter pylori eradication activity, and GPCR inhibitory activity, and is therefore a useful substance for preventing and treating gastrointestinal ulcers, gastritis, reflux esophagitis, or gastrointestinal damage caused by Helicobacter pylori. In addition, not only the compound but also pharma- ceutically acceptable salts of the compound can be used in the present invention.
[0010] In addition, the present invention can use pharma- ceutically acceptable salts of the compound represented by Chemical Formula 1. As the salt, salts commonly used in the art, such as acid addition salts formed with pharma- ceutically acceptable free acids, can be used without limitation. The term "pharma-ceutically acceptable salt" in the present invention refers to any organic or inorganic addition salt of the compound represented by Chemical Formula 1, which has a relatively non-toxic and harmless effective concentration in a patient and does not reduce the beneficial efficacy of the compound due to side effects caused by the salt.
[0011] A pharma- ceutically acceptable salt can be obtained by a conventional method using an inorganic or organic acid. For example, the compound represented by Chemical Formula 1 can be dissolved in a water-miscible organic solvent, such as acetone, methanol, ethanol, or acetonitrile, and an organic or inorganic acid can be added to the solution, and the precipitated crystals can be filtered and dried to obtain a pharma-ceutically acceptable salt. Alternatively, the solvent or excess acid can be removed from the reaction mixture to which the acid has been added under reduced pressure, and the residue can be dried, or another organic solvent can be added to the solution, and the precipitated salt can be filtered to obtain a salt. In this case, preferred salts include salts derived from hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, or toluenesulfonic acid.
[0012] In the present invention, the chemotherapeutic agent is used together with the compound represented by Formula 1 or a pharma- ceutically acceptable salt thereof for the prevention or treatment of triple-negative breast cancer, and specifically means a substance having cytotoxicity as a chemical substance for the treatment of cancer. Examples of chemotherapeutic agents that can be used in the present invention include anthracyclines such as doxorubicin, and taxanes such as docetaxel and paclitaxel.
[0013] The disease to be prevented or treated in the present invention is triple-negative breast cancer, which means breast cancer in which estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are all negative. Therefore, although there are limited therapeutic agents other than existing anti-cancer chemotherapy, triple-negative breast cancer can be prevented or treated by using the compound represented by Formula 1 or a pharma- ceutically acceptable salt thereof together with a chemotherapeutic agent as in the present invention. In addition, the triple-negative breast cancer may be caused by overexpression of V-ATPase.
[0014] As used herein, the term "prevention" refers to any action that inhibits or delays the onset, spread, and recurrence of the disease by administering a composition of the invention, and "treatment" refers to any action that ameliorates or favorably alters the symptoms of the disease by administering a composition of the invention.
[0015] Preferably, the molar ratio of the compound represented by Chemical Formula 1, or a pharma- ceutically acceptable salt thereof, and the chemotherapeutic agent is 5: 1 or more, and preferably, the molar ratio of the compound represented by Chemical Formula 1, or a pharma- ceutically acceptable salt thereof, and the chemotherapeutic agent is 30: 1 or less.
[0016] More preferably, the molar ratio (a:b) of the compound represented by Chemical Formula 1, or a pharma- ceutically acceptable salt thereof (a) and the chemotherapeutic agent (b) is 6:1 or more, 7:1 or more, 8:1 or more, 9:1 or more, or 9.5:1 or more, and is 25:1 or less, 24:1 or less, 23:1 or less, 22:1 or less, 21:1 or less, 20:1 or less, 19:1 or less, 18:1 or less, 17:1 or less, 16:1 or less, 15:1 or less, 14:1 or less, 13:1 or less, 12:1 or less, or 11:1 or less.
[0017] In addition, when the chemotherapeutic agent is doxorubicin, it is preferable that the molar ratio (a:b') of the compound represented by Chemical Formula 1 or a pharma- ceutical acceptable salt thereof (a) and doxorubicin (b') is 9.5:1 or more and 11:1 or less.
[0018] In addition, when the chemotherapeutic agent is docetaxel, it is preferable that the molar ratio (a:b") of the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof (a) and docetaxel (b") is 1000:1 or more. It is also preferable that the molar ratio (a:b") of the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof and docetaxel is 100,000:1 or less.
[0019] The pharmaceutical composition of the present invention can be formulated into oral or parenteral dosage forms according to standard pharmaceutical practice. These dosage forms can contain, in addition to the active ingredient, pharma- ceutical acceptable carriers, adjuvants, diluents, and other additives.
[0020] Suitable carriers include, but are not limited to, physiological saline, polyethylene glycol, ethanol, vegetable oil, and isopropyl myristate, and diluents include, but are not limited to, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and / or glycine. The compound of the present invention can also be dissolved in oil, propylene glycol, or other solvents that are commonly used to prepare injection solutions. The compound of the present invention can also be formulated into ointments or creams for topical application.
[0021] The preferred dose of the active ingredients (the compound represented by the above Chemical Formula 1 or a pharma- ceutically acceptable salt thereof, and the chemotherapeutic agent) contained in the composition of the present invention varies depending on the condition and body weight of the patient, the severity of the disease, the drug form, the administration route, and the duration, and can be appropriately selected by those skilled in the art. However, for a favorable effect, each of the active ingredients contained in the composition of the present invention is administered at 0.0001 to 100 mg / kg (body weight) per day, preferably 0.001 to 100 mg / kg (body weight). The dosage can be administered once a day or in divided doses via oral or parenteral routes.
[0022] Depending on the method of administration, the pharmaceutical composition may contain the active ingredient in an amount of 0.001 to 99% by weight, preferably 0.01 to 60% by weight, based on the total amount of the active ingredient.
[0023] The pharmaceutical compositions according to the invention can be administered by a variety of routes to mammals, including rats, mice, livestock, and humans, etc. All modes of administration are envisaged, for example, oral, rectal, or by intravenous, intramuscular, subcutaneous, intrauterine, intradural, or intracerebral vascular (intracerebroventricular) injection. Effect of the Invention
[0024] The aforementioned pharmaceutical composition according to the present invention can be useful for preventing or treating triple-negative breast cancer. [Brief description of the drawings]
[0025] [Figure 1] 1 shows the results of Experimental Example 1 of the present invention, and is a graph illustrating the results of evaluating antitumor efficacy through co-administration of doxorubicin. [Diagram 2] 1 shows the results of Experimental Example 2 of the present invention, and is a graph showing the evaluation results according to the molar ratio of combined use with doxorubicin. [Diagram 3] 1 shows the results of Experimental Example 2 of the present invention, and is a graph showing the evaluation results according to the molar ratio of esomeprazole used in combination. [Figure 4] 1 shows the results of Experimental Example 3 of the present invention, and graphically illustrates the evaluation of antitumor efficacy by combined administration of docetaxel. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0026] In the following, preferred examples are presented to aid in understanding the present invention. However, the following examples are merely illustrative of the present invention, and the scope of the present invention is not limited to the following examples. EXAMPLES
[0027] Manufacturing Example JPEG2024544082000003.jpg5067 The compound represented by Chemical Formula 1 of the present invention was prepared in the same manner as in Example 8 of Korean Patent Application No. 10-2016-0013588, and is hereinafter named "Fexuprazan".
[0028] Molecular weight 446.87 1H-NMR (500MHz, MeOD): 7.69 (s, 1H), 7.58-7.53 (m, 1H), 7.45 (t, 1H), 7.30 (d, 1) H), 7.20-7.15(m, 2H), 7.02-6.94(m, 2H), 4.07(d, 2H), 3.46(s, 3H), 2.71(s, 3H)
[0029] Meanwhile, the chemotherapeutic agents used in conjunction with the compounds were commercial products of doxorubicin and docetaxel.
[0030] Experimental Example 1: Evaluation of antitumor efficacy through combined administration of doxorubicin To confirm the anti-cancer efficacy of co-administration of fexprazan and doxorubicin, cell proliferation was measured for Hs578T (human triple-negative breast cancer cell line) using the CellTiter-Glo® Luminescent Cell Viability (Promega, Catalog #G7571) method. This method is a method to confirm cell viability by measuring the enzyme activity at this time when the luciferase enzyme is activated by ATP released from living cells and reacts with the luciferin substrate.
[0031] Specifically, each cancer cell line was prepared in 100uL of cell culture medium (RPMI medium, 10% FBS, 1% P / S, 4.5g / L D-glucose, 2.383g / L HEPES buffer, L-Glutamine, 1.5g / L sodium bicarbonate, 110mg / L sodium pyruvate) in a white clear-bottom 96 well microplate. Fexprazan 10uM and doxorubicin 1uM were administered alone and in combination, respectively, and vonoprazan 10uM was administered alone and in combination with doxorubicin as a comparison group. At this time, 0.1% DMSO was used as the solvent for each composition. The vehicle control was 0.1% DMSO. Each experimental group was repeated twice. Plates treated with compounds at each concentration were incubated in a 37℃, 5% CO2 incubator for 48 hours, and 100uL / well of substrate solution containing luciferin was added to a white clear-bottom 96 well microplate to initiate the enzymatic reaction. The reaction was allowed to proceed in the dark at room temperature for 10 minutes, and luminescence was measured using a Flexstation3 multi-mode microplate reader. Luciferase enzyme activity, which represents the amount of ATP, was measured by chemiluminescence according to the CellTiter-Glo® Luminescent Cell Viability manual, and inhibitory activity was calculated. The results of each compound were analyzed using Microsoft Accelerometer, and the compound concentrations were converted to log values using Graphpad Prism software and displayed on a graph.
[0032] [Table 1]
[0033] As can be seen from Table 1 and FIG. 1, fexprazan has a superior antitumor effect when administered in combination with the chemotherapeutic agent doxorubicin, as compared to administration alone.
[0034] In addition, vonoprazan has no synergistic effect with doxorubicin, and it can be confirmed that it is impossible to predict whether a synergistic effect will occur when a general gastric acid secretion inhibitor or P-CAB is used with doxorubicin.
[0035] Experimental Example 2: Confirmation of optimal combination molar ratio with doxorubicin To confirm the optimal combination ratio of fexprazan to doxorubicin, cell proliferation was measured using the CellTiter-Glo® Luminescent Cell Viability (Promega, Catalog #G7571) method in the same manner as in Experimental Example 1. In addition to a group administered with 1uM doxorubicin alone, experimental groups were treated with 1uM doxorubicin and 0.1, 0.5, 1, 5, 10, 15, and 20uM fexprazan in combination, and the vehicle control was 0.1% DMSO. Additionally, esomeprazole was treated under the same conditions to compare the effect of combination with fexprazan. The cells were cultured in a 37°C, 5% CO2 incubator for 48 hours, and the luciferase enzyme activity, which represents the amount of ATP, was measured by chemiluminescence according to the CellTiter-Glo® Luminescent Cell Viability manual, and the inhibitory activity of the compound for this purpose was calculated. The results of each compound were analyzed using Microsoft Accelerator, and the significance was confirmed through an unpaired t test using Graphpad Prism software.
[0036] [Table 2]
[0037] As can be seen from Table 2 and Figures 2 and 3 above, compared to the combined effect of esomeprazole and a chemotherapy drug, it was confirmed that there was a synergistic effect when the molar ratio of doxorubicin to fexprazan was 1:5 or more, and that the synergistic effect was particularly excellent when the molar ratio was 1:10 or more.
[0038] Experimental Example 3: Docetaxel combination administration and antitumor efficacy evaluation To confirm the possibility of using docetaxel and fexprazan in combination, the cell proliferation was measured by CellTiter-Glo® Luminescent Cell Viability (Promega, Catalog #G7571) method in the same manner as in Experimental Example 1 when the cells were administered alone or in combination. Hs578T (human triple negative breast cancer cell line) was cultured in a 96-well clear bottom plate and stabilized for 24 hours. The optimal concentration of fexprazan was 10uM, which was derived based on the previous experimental results, and docetaxel was treated to the cells at a concentration of 1nM and 10nM, which are the effective cytotoxic doses on cell viability. As an experimental group for comparison, esomeprazole was treated at 10uM, the same as fexprazan, and the vehicle control was 0.1% DMSO. After culturing for 48 hours in a 5% CO2 incubator at 37℃, the luciferase enzyme activity, which represents the amount of ATP, was measured by chemiluminescence according to the CellTiter-Glo® Luminescent Cell Viability manual, and the inhibitory activity was calculated. Each result was analyzed using Microsoft Accelerometer, and the significance was confirmed by unpaired t-test analysis using Graphpad Prism software.
[0039] [Table 3]
[0040] As can be seen from Table 3 and FIG. 4 above, it can be seen that the chemotherapeutic agent docetaxel also has synergistic antitumor effects compared to esomeprazole.
Claims
1. A compound represented by the following formula 1, or a pharma- ceutically acceptable salt thereof: including chemotherapy agents, A pharmaceutical composition for preventing or treating triple negative breast cancer. [Chemical formula 1]
2. 2. The pharmaceutical composition of claim 1, wherein the chemotherapeutic agent is doxorubicin or docetaxel.
3. 2. The pharmaceutical composition of claim 1, wherein the molar ratio of the compound represented by Formula 1, or a pharma- ceutically acceptable salt thereof, and the chemotherapeutic agent is 5:1 or greater.
4. the chemotherapeutic agent is doxorubicin; The pharmaceutical composition according to claim 1, wherein the molar ratio of the compound represented by Formula 1, or a pharma- ceutically acceptable salt thereof, and doxorubicin is 9.5:1 or more and 11:1 or less.
5. the chemotherapeutic agent is docetaxel; The pharmaceutical composition of claim 1, wherein the molar ratio of the compound represented by Formula 1, or a pharma- ceutically acceptable salt thereof, and docetaxel is 1000:1 or more.
6. The pharmaceutical composition of claim 1, wherein the triple negative breast cancer is due to V-ATPase overexpression.
Citation Information
Patent Citations
Pyrrole compounds
JP2012501296A
Methods of treating cancer with coenzyme q10 combination therapy
JP2016519103A
Novel 4-methoxypyrrole derivative or its salt and pharmaceutical composition containing the same
JP2017538716A
Electrophiles and electrophile pro-drugs as RAD51 inhibitors
WO2020102529A1
